Work

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.9003

Authors: Myung-Ju Ahn, Dong-Wan Kim, Tae Min Kim, Chia-Chi Lin, Jayantha Ratnayake, David J Carlie, Xiaolu Yin, Zhenfan Yang, Haiyi Jiang, James Chih-Hsin Yang

Institutions: Samsung Medical Center, Sungkyunkwan University, Seoul National University Hospital, Seoul National University, National Taiwan University Hospital, AstraZeneca (United Kingdom), National Taiwan University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2512939901

Cites:

Cited by: 41

Related to: 10